This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

HomeEfficacyATGAM® efficacyEfficacy homeTrial: ATGAM® versus rabbit ATGTrial: ATGAM® ± sirolimusTrial: ATGAM® other pivotal studiesSafetyDosing & administrationSupport & resourcesMaterialVideo

Information on how to access prescribing information and adverse event reporting can be found towards the bottom of the page.

ATGAM®▼ (horse anti-human T-lymphocyte immunoglobulin) efficacy



Atgam is indicated for use in adults and in children aged 2 years and older for the treatment of acquired moderate to severe aplastic anaemia of known or suspected immunologic aetiology as part of standard immunosuppressive therapy in patients who are unsuitable for haematopoietic stem cell transplantation (HSCT) or for whom a suitable HSC donor is not available.

ATGAM® is associated with partial or complete haematologic recoverya and improved survival rates in patients with aplastic anaemia of known or suspected immunologic aetiology in patients who are unsuitable for bone marrow transplant1, 3-6

Key points from the five clinical studies1, 3-6

Example

The efficacy data for ATGAM are derived from five clinical
studies1, 3-6

One study compared 77 patients treated with ATGAM® + CsA across 4 days with or without the addition of the immunosuppressant drug, sirolimus.1, 3

Learn more

Another study investigated 120 patients treated with ATGAM® + CsA versus rabbit ATG + CsA.1, 4

Learn more

Three studies evaluated the efficacy of ATGAM® across 8 or 10 days in a total of 115 patients with moderate-to-severe aplastic anaemia.1, 5, 6

Learn more

The haematologic response ratesb with ATGAM® + CsA at 6 months were statistically superior to those for rabbit ATG + CsA, those with ATGAM showing response rates of 68% versus 37% for rATG (p<0.001)4Current guidelines recommend the standard first-line IST for the treatment of acquired moderate-to-severe aplastic anaemia in patients who are unsuitable for HSCT is ATG derived from horse, combined with another immune system-inhibiting drug, CsA1,2AA, aplastic anaemia; ATG, anti-thymocyte globulin; CsA, ciclosporin A; HSCT, haematopoietic stem-cell transplantation; IST, immunosuppressive therapy; HSC, haematopoietic stem cell.

aHematologic response is defined differently in different studies. This will be defined throughout when referring to specific studies.
bHematologic response defined as no longer meeting criteria for severe aplastic anaemia.2References:ATGAM® Summary of Product Characteristics. Pfizer Inc. Killick SB, et al. Br J Haematol. 2016;172(2):187–20; Scheinberg P, et al. Haematologica. 2009;94(3):348–54.Scheinberg P, et al. N Engl J Med. 2011;365(5):430–8.Champlin R, et al. N Engl J Med. 1983;308:113-118Champlin RE, et al. Blood. 1985;66:184-188
Prescribing Information
Click here for Prescribing Information for ATGAM (horse anti-human T-lymphocyte immunoglobulin)ATGAM® efficacyLearn about the safety profile of ATGAM®  Find out more LoadingLearn about ATGAM® dosing & administration Find out more LoadingMore information is available in support & resources Find out more Loading
PP-ATG-GBR-0025. February 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​